HT
ITCI

HAP Trading’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

HAP Trading’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-225,000
Closed -$711K – 897
2024
Q1 		$711K Buy
+225,000
New +$15.5M 0.08% 154
2022
Q1 		– Sell
-14,100
Closed -$174K – 2884
2021
Q4 		$174K Buy
+14,100
New +$592K ﹤0.01% 1066
2021
Q1 		– Sell
-54,100
Closed -$78K – 2658
2020
Q4 		$78K Sell
54,100
-4,800
-8% -$126K ﹤0.01% 1268
2020
Q3 		$144K Sell
58,900
-581,200
-91% -$13.3M 0.01% 725
2020
Q2 		$1.32M Buy
640,100
+627,200
+4,862% +$12.7M 0.07% 230
2020
Q1 		$32K Sell
12,900
-624,200
-98% -$13.6M ﹤0.01% 853
2019
Q4 		$12.2M Buy
637,100
+621,700
+4,037% +$7.46M 0.67% 29
2019
Q3 		$18K Sell
15,400
-20,100
-57% -$193K ﹤0.01% 961
2019
Q2 		$120K Buy
+35,500
New +$455K 0.01% 576
2017
Q3 		– Sell
-31,000
Closed -$3K – 1117
2017
Q2 		$3K Sell
31,000
-900
-3% -$10.4K ﹤0.01% 902
2017
Q1 		$52K Buy
+31,900
New +$462K ﹤0.01% 677
2016
Q4 		– Sell
-31,800
Closed -$14K – 1261
2016
Q3 		$14K Buy
+31,800
New +$1.29M ﹤0.01% 936

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HAP Trading's ITCI Position: Q2 2024 in Review

HAP Trading sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 68,011 shares — an estimated $4.71M sold.

HAP Trading first reported a position in ITCI in Q3 2017 and held it in 4 quarters. The position peaked at $4.71M in Q1 2024. 375 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

  • HAP Trading reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
  • HAP Trading sold 68,011 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $4.71M.
  • HAP Trading first reported a position in Intra-Cellular Therapies Inc. in Q3 2017 and held it in 4 quarters.
  • HAP Trading's Intra-Cellular Therapies Inc. position peaked at $4.71M in Q1 2024.
  • 375 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on HAP Trading's 13F filing for Q2 2024, filed 14 Aug 2024.